Gastroenterology
Volume 130, Issue 3 , Pages 632-638 , March 2006

Peginterferon Alfa-2b Therapy in Acute Hepatitis C: Impact of Onset of Therapy on Sustained Virologic Response

  • Sanaa M. Kamal

      Affiliations

    • Division of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    • Department of Gastroenterology and Liver Diseases, Ain Shams University, Cairo, Egypt
    • Department of Gastroenterology and Hepatology, University of Freiburg, Freiburg, Germany
    • Corresponding Author InformationAddress requests for reprints to: Sanaa M. Kamal, MD, Liver Disease Center, Beth Israel Deaconess Medical Center, 4 Blackfan Circle, Boston, Massachusetts 02115.fax:
    • ,
  • Amr E. Fouly

      Affiliations

    • Department of Gastroenterology and Liver Diseases, Ain Shams University, Cairo, Egypt
    • ,
  • Refaat R. Kamel

      Affiliations

    • Department of Gastroenterology and Liver Diseases, Ain Shams University, Cairo, Egypt
    • ,
  • Bridgette Hockenjos

      Affiliations

    • Department of Gastroenterology and Hepatology, University of Freiburg, Freiburg, Germany
    • ,
  • Ahmed Al Tawil

      Affiliations

    • Department of Gastroenterology and Liver Diseases, Ain Shams University, Cairo, Egypt
    • ,
  • Khalifa E. Khalifa

      Affiliations

    • Department of Gastroenterology and Liver Diseases, Ain Shams University, Cairo, Egypt
    • ,
  • Qi He

      Affiliations

    • Division of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    • ,
  • Margaret J. Koziel

      Affiliations

    • Division of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    • ,
  • Khairy M. El Naggar

      Affiliations

    • Department of Gastroenterology and Liver Diseases, Ain Shams University, Cairo, Egypt
    • ,
  • Jens Rasenack

      Affiliations

    • Department of Gastroenterology and Hepatology, University of Freiburg, Freiburg, Germany
    • ,
  • Nezam H. Afdhal

      Affiliations

    • Division of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Received 23 August 2005 ,Accepted 21 December 2005.

References 

  1. Hoofnagle JH . Course and outcome of hepatitis C . Hepatology . 2002;36(Suppl):S21–S29
  2. Liang TJ , Rehermann B , Seeff LB , Hoofnagle JH . Pathogenesis, natural history, treatment, and prevention of hepatitis C . Ann Intern Med . 2000;132:296–305
  3. Alter MJ . The epidemiology of acute and chronic hepatitis C . Clin Liver Dis . 1997;1:559–568
  4. Orland JR , Wright TL , Cooper S . Acute hepatitis C . Hepatology . 2001;33:321–327
  5. Kamal SM , Amin A , Madwar M , et al.   Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients . J Virol . 2004;78:12252–12258
  6. Nakayama H , Sugai Y , Ikeya S , Inoue J , Nishizawa T , Okamoto H . Molecular investigation of interspousal transmission of hepatitis C virus in two Japanese patients who acquired acute hepatitis C after 40 or 42 years of marriage . J Med Virol . 2005;75:258–266
  7. Omata M , Yokosuka O , Takano S , et al.   Resolution of acute hepatitis C after therapy with natural beta interferon . Lancet . 1991;338:914–915
  8. Hwang SJ , Lee SD , Chan CY , Lu RH , Lo KJ . A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C . J Hepatol . 1994;21:831–836
  9. Lampertico P , Rumi M , Romeo R , et al.   A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C . Hepatology . 1994;19:19–22
  10. Vogel W , Graziadei I , Umlauft F , et al.   High-dose interferon-alfa-2b treatment prevents chronicity in acute hepatitis C (a pilot study) . Dig Dis Sci . 1996;41(Suppl):81S–85S
  11. Calleri G , Colombatto P , Gozzelino M . Natural beta interferon in acute type-C hepatitis patients (a randomized controlled trial) . Ital J Gastroenterol Hepatol . 1998;30:181–184
  12. Jaeckel E , Cornberg M , Wedemeyer H , et al.   Treatment of acute hepatitis C with interferon alfa-2b . N Engl J Med . 2001;345:1452–1457
  13. Gerlach JT , Diepolder HM , Zachoval R , et al.   Acute hepatitis C (high rate of both spontaneous and treatment-induced viral clearance) . Gastroenterology . 2003;125:80–88
  14. Nomura H , Sou S , Tanimoto H , Nagahama T , Kimura Y , Hayashi I . Short-term interferon-alfa therapy for acute hepatitis C . Hepatology . 2004;39:1213–1219
  15. Manns MP , McHutchison JG , Gordon SC , et al.   Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C (a randomized trial) . Lancet . 2001;358:958–965
  16. Fried MW , Shiffman ML , Reddy R , et al.   Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection . N Engl J Med . 2002;347:975–982
  17. Zeuzem S , Feinman SV , Rasenack J , et al.   Peginterferon alfa-2a in patients with chronic hepatitis C . N Engl J Med . 2000;343:1666–1672
  18. Kamal SM , El Tawil A , Nakano T , et al.   Peginterferon-alpha 2b and ribavirin therapy in chronic hepatitis C genotype 4 (impact of treatment duration and viral kinetics on sustained virologic response) . Gut . 2005;54:858–866
  19. Lindsay KL , Trepo C , Heintges T , et al.   A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C . Hepatology . 2001;34:395–403
  20. Kamal SM , Ismail A , Graham CS , et al.   Pegylated interferon alpha therapy in acute hepatitis C (relation to hepatitis C virus-specific T cell response kinetics) . Hepatology . 2004;39:1721–1731
  21. Farci P , Strazzera R , Alter HJ , Farci S , Degioannis D , Coiana A , et al.   Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome . Proc Natl Acad Sci U S A . 2002;99:3081–3086
  22. Wiegand J , Jackel E , Cornberg M , et al.   Long-term follow-up after successful interferon therapy of acute hepatitis C . Hepatology . 2004;40:98–107
  23. Gerlach T , Diepolder H , Jung M , et al.   Recurrence of hepatitis C virus after loss of virus specific CD 4 + T-cell response in acute hepatitis C . Gastroenterology . 1999;117: 993–941
  24. Kamal SM , Rasenack JW , Bianchi L , et al.   Acute hepatitis C without and with schistosomiasis (correlation with hepatitis C-specific CD4 (+) T-cell and cytokine response) . Gastroenterology . 2001;121:646–656

 Supported by the National Institutes of Allergy and Infectious Diseases (grant nos. R21 AI054887, R21 AI41563, and R01 AI068966); Fulbright Commission, USA (TEMPUS: grant no. IMG 04-E.G. 1096); Alexander von Humboldt Foundation, Germany; and International Society of Infectious Diseases, USA (grant no. RF-9641).

PII: S0016-5085(06)00061-8

doi: 10.1053/j.gastro.2006.01.034

Gastroenterology
Volume 130, Issue 3 , Pages 632-638 , March 2006

Article Tools

* Image Usage & Resolution